The collaboration funds a multi-year effort to advance a novel ANO5 gene replacement therapy from early development through clinical trial readiness for patients with LGMD2L. Cure Rare Disease (CRD), a nonprofit biotechnology organization dedicated to advancing treatments for rare and…
CFO’s Strategic Leadership Bolsters First American’s Financial Position and Industry Leadership What does it take to lead a company through a dynamic real estate market? First American Financial Corporation (NYSE: FAF), a premier provider of title, settlement, and risk solutions…
Hospital for Special Surgery shares new research highlighting improved recovery, safety, and long-term outcomes through optimized perioperative medication strategies in hip and knee replacement patients. Hospital for Special Surgery (HSS), widely recognized as the world’s leading academic medical center dedicated…
Ouster’s Q4 2025 Results Highlight Strong Growth and Profitability in Digital Lidar Market How can companies stay ahead in the rapidly evolving landscape of Physical AI? Ouster, Inc. a leader in sensing and perception for Physical AI, has provided a…
Acadia Pharmaceuticals plans to challenge the negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use regarding trofinetide for patients with Rett syndrome aged two and older. Acadia Pharmaceuticals Inc.has announced that the Committee for Medicinal…
Elanco Animal Health Incorporated today announced U.S. Department of Agriculture (USDA) approval of TruCan™ Ultra B (Oral), an innovative oral vaccine designed to help protect dogs against Bordetella bronchiseptica, one of the primary pathogens associated with canine infectious respiratory disease…
Almirall, a global pharmaceutical company focused exclusively on medical dermatology, has announced plans to initiate a Phase III clinical study evaluating the efficacy and safety of lebrikizumab in adult patients with nummular eczema. The study, named LumiNE, is scheduled to…
Orion Revamps Packaging to Boost Patient Experience and Sustainability Since 2020, Orion has been systematically reimagining its product packaging with a dual focus on patient safety and environmental sustainability. This ongoing effort has touched every stage of the supply chain—from…
argenx SE a global immunology company focused on transforming outcomes for patients with severe autoimmune diseases, has announced a significant regulatory milestone for its flagship therapy, VYVGART® (IV: efgartigimod alfa-fcab). The U.S. Food and Drug Administration (FDA) has accepted the…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for…